Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
19/10/26	KRW 17,180.00	+2.26%	121,792
16/10/26	KRW 16,800.00	+4.87%	200,271
15/10/26	KRW 16,020.00	-9.54%	213,731
14/10/26	KRW 17,710.00	+4.05%	271,494
13/10/26	KRW 17,020.00	-4.49%	238,499

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 19/10/2026			5-day change	1st Jan Change
17,180.00 ^KRW	+2.26%		-10.85%	-85.68%

14/10	Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate	CI
23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI

Market Cap	374B 281M 251M 232M 211M 396M 26.62B 402M 2.78B 1.09B 13.9B 1.05B 1.03B 44.57B	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	267B 200M 179M 165M 151M 282M 18.99B 287M 1.98B 779M 9.92B 751M 735M 31.8B	EV / Sales 2024 *	-	EV / Sales 2025	103,580x
Free-Float	83.68%	Yield 2024 *	-	Yield 2025	-

14/10	Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate	CI
23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
16/07	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
18/04	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
13/04	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
16/01	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
05/01	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
18/12	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
04/11	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/10/25	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/06/25	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/02/25	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/07/24	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

23/08	Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate	AQ
20/12	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
16/10/25	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Stock

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation: Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news: Orum Therapeutics, Inc.

Press Releases: Orum Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	+2.26%
1 week	-10.85%
Current month	-22.44%
1 month	-54.06%
3 months	-62.16%
6 months	-80.00%
Current year	-85.68%

1 week	15,690	18,410
1 month	15,690	29,050
Current year	15,690	146,600
1 year	15,690	146,600
3 years	15,690	146,600
5 years	15,690	146,600
10 years	15,690	146,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	17/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	23/10/2023
Chad May CTO	Chief Tech/Sci/R&D Officer	-	05/01/2026

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	17/08/2016
In-Tae Jeong BRD	Director/Board Member	44	23/10/2023
Un-Nam Park BRD	Director/Board Member	55	01/04/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/2/25	Seung-Ju Lee	Free	Founder	3,388,000	-
21/2/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-
21/2/25	Un-Nam Park	Free	Director	60,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	+2.26%	-10.85%	-46.56%	-	274M
WUXI APPTEC CO., LTD.	+1.52%	-7.16%	+51.66%	+67.41%	65B
LONZA GROUP AG	+1.52%	+7.17%	+10.77%	+77.89%	51.2B
ARGENX SE	+0.30%	+0.19%	+2.53%	+56.14%	51.19B
IQVIA HOLDINGS INC.	-0.38%	+2.31%	+29.98%	+40.71%	43.93B
BEONE MEDICINES AG	+0.30%	+4.43%	+16.99%	+120.94%	41.96B
REVOLUTION MEDICINES, INC.	+2.35%	-4.01%	+236.69%	+497.21%	38.14B
CELLTRION, INC.	+2.16%	+10.36%	+18.92%	+59.70%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	+1.80%	25.2B
GENMAB A/S	+1.60%	+3.97%	+21.34%	+22.33%	22.5B
Average	+1.07%	+0.22%	+37.94%	+104.90%	37.26B
Weighted average by Cap.	+0.97%	+0.04%	+45.96%	+106.36%

	2024	2025
Net sales	20.91B 15.7M 14.03M 12.96M 11.81M 22.14M 1.49B 22.47M 156M 61.09M 778M 58.87M 57.62M 2.49B	23.56M 17.7K 15.81K 14.61K 13.31K 24.95K 1.68M 25.33K 175K 68.85K 876K 66.36K 64.94K 2.81M
Net income	-5.74B -4.31M -3.85M -3.56M -3.24M -6.08M -409M -6.17M -42.73M -16.77M -214M -16.16M -15.82M -685M	-41.97B -31.52M -28.16M -26.02M -23.71M -44.45M -2.99B -45.12M -312M -123M -1.56B -118M -116M -5.01B
Net Debt	-90.47B -67.94M -60.7M -56.09M -51.12M -95.81M -6.45B -97.25M -673M -264M -3.37B -255M -249M -10.79B	-107B -80.43M -71.87M -66.4M -60.51M -113M -7.63B -115M -797M -313M -3.98B -302M -295M -12.77B